318 results about "Pulmonary emphysema" patented technology

Embodiments of the present invention provide a method for treatment of respiratory disorders such as asthma, chronic obstructive pulmonary disease, and chronic sinusitis, including cystic fibrosis, interstitial fibrosis, chronic bronchitis, emphysema, bronchopulmonary dysplasia and neoplasia. The method involves administration, preferably oral, nasal or pulmonary administration, of anti-inflammatory and anti-proliferative drugs (rapamycin or paclitaxel and their analogues).

Devices and methods are provided for assessing the condition of tissue, in particular to diagnose the location and stage of diseases such as emphysema. In one device or method according to the invention, sound is introduced into lung tissue. A portion of the sound is detected after it has passed through a portion of the lung. A sound-propagation parameter is determined by comparing a property of the introduced sound and a property of the detected sound. A region of examination of the tissue is identified, based in part on either a property of the component that introduces the sound or a property of the component that detects the sound. The condition of the tissue is assessed in the region of examination, based in part on the sound-propagation parameter.

An apparatus and method of detecting COPD and in particular, emphysema utilizes a change in acoustic transmission characteristics of a lung due to e.g. the appearance of fenestrae (perforations) in the alveoli of the lung. The use of acoustic signals may provide good sensitivity to the existence of alveolar fenestrae, even for microscopic emphysema, and the appearance and increase in fenestrae may be determined by monitoring acoustic transmission characteristics such as, for example, an increase in acoustic signal velocity and velocity dispersion, and / or a change in attenuation. A transmitter may be located in e.g. the supra-clavicular space and receivers may be mounted on the chest. Measurements may be correlated between pairs of receivers to determine acoustic transmission profiles.

A migration learning lung lesion tissue detection system based on an MaskScoring R-CNN network comprises a storage module for storing four lung diseases including lung cancer, pneumonia, pulmonary tuberculosis and emphysema and further comprises a diagnosis module, and the diagnosis module is in communication connection with the storage module and comprises the following steps of 1) preprocessinga medical image; 2) constructing the MaskScoring R-CNN network model, wherein the step 2) specially comprises 1, constructing a shared convolutional neural network backbone (for feature extraction); 2, carrying out transfer learning on a shared convolutional neural network; 3, constructing an FPN network; 4, constructing an RPN network; 5, constructing an ROIAlign layer; 6, adding the MaskIoU head; and 3) identifying the lung medical image lesion tissue, inputting a to-be-detected lung CT image into the constructed MaskScoring R-CNN network, outputting and obtaining an identified image by thenetwork, framing out and masking the identified lesion tissues, and marking the lesion categories. According to the method, the requirement for high precision of medical image segmentation is met, andthe network can have the good generalization.

The present application provides sodium channel blockers exemplified by the following structure:The compounds of the invention useful for treating chronic bronchitis, cystic fibrosis, sinusitis, vaginal dryness, dry eye, Sjogren's disease, distal intestinal obstruction syndrome, dry skin, esophagitis, dry mouth (xerostomia), nasal dehydration, ventilator-induced pneumonia, asthma, primary ciliary dyskinesia, otitis media, chronic obstructive pulmonary disease, emphysema, pneumonia, constipation, and chronic diverticulitis, for example.

The present invention is related to:(i) matrix metalloproteinase inhibitors containing sulfonylamino acid derivatives of the formula (Ia):wherein R1 is hydrogen, C1-4 alkyl; R is hydrogen, C1-8 alkyl etc.; E is -CONR3-, in which R3 is hydrogen, C1-4 alkyl etc., -NR3CO-, -CO-O-, -O-CO- etc.; A is hydrogen, C1-8 alkyl, C3-7 cycloalkyl, or Ar; J is bond, C2-4 alkylene etc.; G is -(CH2)m- in which m is 2, 3 or 4, orin which R6 and R7 is hydrogen, C1-8 alkyl etc.; and non-toxic salts thereof,(ii) novel sulfonylamino acid derivatives of the formula (Ib):wherein all the symbols are the same meaning as (i); and non-toxic salts thereof, and(iii) process for the preparation of the compound of the formula (Ib). The compounds of the formula (Ia) are useful for prevention and / or treatment of diseases induced by overexpression and excess activity of MMP. The diseases such as above, for example, are rheumatoid, arthrosteitis, unusual bone resorption, osteoporosis, periodontitis, interstitial nephritis, arteriosclerosis, pulmonary emphysema, cirrhosis, cornea injury, metastasis of, invasion of or growth of tumor cell, autoimmune disease (Crohn's disease, Sjogren's syndrome etc.), disease caused by vascular emigration or infiltration of leukocytes, arterialization.

The medicinal wine for treating trachitis, pulmonary emphysema and dyspneic cough is one kind of orally taken medicine including two parts, medicinal wine A and medicinal wine B. The medicinal wine A is prepared through soaking 27 kinds of Chinese medicinal materials, including pinellia tuber, almond, aster root, etc. in certain weight proportion in kaoliang spirit with 50 % alcohol content; and The medicinal wine B is prepared through soaking 27 kinds of Chinese medicinal materials, including prepared rhizome of rehmannia, gecko, white atractylodes rhizome, etc. in certain weight proportion in kaoliang spirit with 50 % alcohol content. The medicinal wine is suitable for treating trachitis, pulmonary emphysema, dyspneic cough, chronic pharyngitis, laryngitis and other diseases.

The present invention relates to the use of an elastase inhibitor, preferably fahsin for the treatment or prevention of emphysema, COPD or lung cancer. The elastase inhibitor is preferably administered through inhalation, preferably thorough inhalation of tobacco smoke. The invention also comprises smoking articles comprising such an elastase inhibitor.

The capsule for treating asthma, pulmonary emphysema and SARS is developed based on the principle that the Chinese medicine and the Western medicine are complementary and synergistic, and compounded with several kinds of Chinese medicines and Western medicines. It can kill bacteria, resist virus, eliminate circulating disturbance and regulate immunity, and suitable for various people in different disease stages. It has high and stable curative effect. In addition, it has also certain treating effect on hypertension, angiosclerosis, wind-wetness Bi syndrome, etc.

The present invention discloses an oral solid preparation containing ambroxol hydrochloride and salbutamol active components. It is formed from ambroxol hydrochloride, salbutamol and auxiliary material according to a certain mixing ratio. Said oral solid preparation has the obvious synergistic action for remitting the symptoms of dyspnea, etc. due to respiratory tract obstruction diseases of bronchial asthma, chronic bronchitis and pulmonary emphysema, etc.

A long term oxygen therapy system having an oxygen supply directly linked with a patient's lung or lungs may be utilized to more efficiently treat hypoxia caused by chronic obstructive pulmonary disease such as emphysema and chronic bronchitis. The system includes an oxygen source, one or more valves and fluid carrying conduits. The fluid carrying conduits link the oxygen source to diseased sites within the patient's lungs. A collateral ventilation bypass trap system directly linked with a patient's lung or lungs may be utilized to increase the expiratory flow from the diseased lung or lungs, thereby treating another aspect of chronic obstructive pulmonary disease. The system includes a trap, a filter / one-way valve and an air carrying conduit. In various embodiments, the system may be intrathoracic, extrathoracic or a combination thereof. In order for the system to be effective, an airtight seal between the parietal and visceral pleurae is required. Chemical pleurodesis is utilized for creating the seal.

The present invention relates to a compound represented by the formula (I),wherein all symbols are as defined in the description,a salt thereof, a solvate thereof, or a prodrug thereof, which has a leukotriene receptor antagonistic activity which is expected to be more effective than those of the leukotriene receptor antagonists currently used in clinical trials. Therefore, it is useful as an agent for the prevention and / or treatment of a leukotriene-mediated disease such as a respiratory diseases such as bronchial asthma, chronic obstructive pulmonary disease, pulmonary emphysema, chronic bronchitis, pneumonia (e.g. interstitial pneumonia etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), allergic rhinitis, sinusitis (e.g. acute sinusitis, chronic sinusitis, etc.), or the like, or as an expectorant or an antiitussive.

The present invention is related to:(i) matrix metalloproteinase inhibitors containing sulfonylamino acid derivatives of the formula (Ia); wherein R1 is hydrogen, C1-4 alkyl; R2 is hydrogen, C1-8 alkyl etc.; E is -CONR3-, in which R3 is hydrogen, C1-4 alkyl etc., -NR3CO-, -CO-O-, -O-CO- etc.; A is hydrogen, C1-8 alkyl, C3-7 cycloalkyl, or Ar; J is bond, C2-4 alkylene etc.; G is -(CH2)m-, in which m is 2, 3 or 4, orin which R6 and R7 is hydrogen, C1-8 alkyl etc.; and non-toxic salts thereof,(ii) sulfonylamino acid derivatives of the formula (Ib):wherein all the symbols are the same meaning as (i); and non-toxic salts thereof, and(iii) process for the preparation of the compound of the formula (Ib).The compounds of the formula (Ia) are useful for prevention and / or treatment of diseases induced by overexpression and excess activity of MMP. The diseases such as above, for example, are rheumatoid, arthrosteitis, unusual bone resorption, osteoporosis, periodontitis, interstitial nephritis, arteriosclerosis, pulmonary emphysema, cirrhosis, cornea injury, metastasis of, invasion of or growth of tumor cell, autoimmune disease (Crohn's disease, Sjogren's syndrome etc.), disease caused by vascular emigration or infiltration of leukocytes, arterialization.

The invention relates to a drug for treating chronic bronchitis and pulmonary emphysema, which is a capsule product prepared by the steps of mixing prepared membranous milkvetch root, prepared apricotseed, perilla fruit, white mustard seed and Chinese olive nut after being processed with coastal glehnia root, dwarf lilyturf tuber, Chinese magnoliavine fruit, green tangerine orange peel, tangerinepeel, unibract fritillary bulb, common coltsfoot flower, pummelo peel, snakegourd seed, perilla stem, perilla fruit and the like, adding water for decoction, then concentrating into a thick paste, drying, smashing, packaging in capsules and carrying out sterilization and disinfection. The drug has the effects of strengthening spleen, benefiting lung, nourishing yin, clearing heat, regulating qi,dissipating phlegm, relieving cough and relieving asthma, is used for treating the chronic bronchitis and the pulmonary emphysema and is characterized by actual efficacy, rapidness, convenience and safe administration, and the clinical observation shows that the total effective rate is 100%.

The present invention relates to a compound represented by the formula (I),wherein all symbols are as defined in the description,a salt thereof, a solvate thereof, or a prodrug thereof, which has a leukotriene receptor antagonistic activity which is expected to be more effective than those of the leukotriene receptor antagonists currently used in clinical trials. Therefore, it is useful as an agent for the prevention and / or treatment of a leukotriene-mediated disease such as a respiratory diseases such as bronchial asthma, chronic obstructive pulmonary disease, pulmonary emphysema, chronic bronchitis, pneumonia (e.g. interstitial pneumonia etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), allergic rhinitis, sinusitis (e.g. acute sinusitis, chronic sinusitis, etc.), or the like, or as an expectorant or an antiitussive.

A medicinal composition for inhalation containing a continuous-release type prodrug of an EP2 agonist topically exhibits a prolonged bronchodilating and antiinflammatory effects. Namely, the medicinal composition for inhalation containing a continuous-release type prodrug of an EP2 agonist is useful as a safe preventive and / or a remedy for respiratory diseases (for example, asthma, pulmonary injury, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, cystic fibrosis, pulmonary hypertension or the like) without causing any systemic effect such as lowering blood pressure. Thus, a safe and useful remedy for respiratory diseases is provided.

Disclosed herein is the treatment of vision loss in a mammal by transplanting an effective amount of hNT-Neuron cells. The treatment can be accomplished by injecting the cells into the retinal area of the eye. Additionally, the cells can be injected into the visual cortex of the brain. Conditions to be treated are vision loss due to optic nerve damage, including glaucoma, optic nerve sheath meningioma and glioma, Graves' ophthalmopathy, benign or malignant orbital tumors, metastatic lesions, tumors arising from the adjacent paranasal sinuses or middle cranial fossa, giant pituitary adenomas, brain tumors or abscesses, cerebral trauma or hemorrhage, meningitis, arachnoidal adhesions, pseudotumor cerebri, cavernous sinus thrombosis, dural sinus thrombosis, encephalitis, space-occupying brain lesions, severe hypertensive disease or pulmonary emphysema.

Implantable artificial bronchi for the treatment of chronic obstructive pulmonary diseases, such as pulmonary emphysema. The implantable artificial bronchus can be made with silicone or nitinol. The embodiments of this invention may be further associated with a one-way valve.

The invention relates to an image report based CT image emphysema automatic labeling method. The method includes the following steps: (1) accomplishing an image report, CT image sequence inputting andimage standardization preprocessing in an input module; (2) extracting the characteristic information, namely the information about emphysema description, in the image report in a phonetic and semantic extraction module according to the technical and rule pattern matching technology of a dictionary; (3) performing regional division on a lung in an emphysema focus extraction module, and performingcluster analysis in a lung area to extract emphysema focus; and (4) obtaining the CT threshold value of each area through calculation according to calculating results of the step 3, labelling the emphysema area of each area in an output and display module, displaying the emphysema areas in a CT image, and giving a quantitative analysis report of lung function. The advantages of the method are that processes during emphysema diagnosis and treatment can be simplified, and medical expenses of patients can be reduced.

The current invention provide novel compounds, methods of treating or preventing emphysema, cancer and dermatological disorders, pharmaceutical compositions suitable for the treatment or prevention of emphysema, cancer and dermatological disorders and methods for delivering formulations into the lung of a mammal suffering from emphysema, cancer and dermatological disorders.

This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides of formula 1and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and / or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.

The pharmaceutical composition comprising the compound of the invention having 8-azaprostaglandin skeleton represented by formula (I)(wherein, all the symbols have the same meanings as that of the specification) a salt thereof, a solvate thereof or a cyclodextrin clathrate thereof, or a prodrug thereof and them as active ingredient have EP4 agonistic action and thus are considered useful for the prevention and / or treatment of immunological diseases, asthma, neuronal cell death, arthritis, lung failure, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardial ischemia, systemic inflammatory response syndrome, sepsis, hemophagous syndrome, macrophage activation syndrome, Still's disease, Kawasaki disease, burn, systemic granulomatosis, ulcerative colitis, Crohn's disease, hypercytokinemia at dialysis, multiple organ failure, shock and glaucoma, etc. Furthermore, the compounds also have an action of accelerating bone formation, so it is expected to be useful for the prevention and / or treatment of diseases associated with loss in bone mass, for example, primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss, osteonecrosis, bone formation after bone operation, alternative treatment for bone grafting.

The present invention provides compositions and methods for the detection, treatment, and prevention of emphysema / COPD. Compositions of the present invention comprise TLR4 activators, Nox3 inhibitors, and Cathepsin E inhibitors useful in the treatment or prevention of emphysema / COPD. Cathepsin E is a downstream effector of TLR4, wherein when cathepsin E is overexpressed in lung of an individual, the individual is at higher risk of developing emphysema / COPD. Cathepsin E is further identified as a biomarker useful in the identification of an individual with, or at-risk of developing emphysema / COPD.

The present invention relates to methods of diagnosing, monitoring, and treating elastin fiber injuries. In additional preferred embodiments, the present invention relates to methods of validating candidate compounds for use in treating chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, refractory asthma, and other related diseases. Examples of such methods include determining if the candidate compound decreases the degradation of elastic fiber in a patient administered the candidate compound by measuring, using mass spectrometry employing an internal standard, a marker of elastic fiber degradation in a sample of a body fluid or a tissue of the patient. The invention provides that a decrease in the presence of the marker compared to a control validates that the candidate compound is effective to treat, prevent, or ameliorate the disease.

The invention discloses Hongshu Xiangyu cake and a production method thereof. The Hongshu Xiangyu cake is made with skimmed milk powder, flour, bulking agent, yeast, ammonium bicarbonate, sweet potato, fragrant taro, sweetener and cream. The production method includes the steps of making mixed mince of the fragrant taro and sweet potato, making fermented flour, making dough, rolling, shaping, and baking. The Hongshu Xiangyu cake made by the production method has the effects of protecting the heart, preventing pulmonary emphysema, preventing diabetics, reducing weight, and enhancing human immunity.

Surfactant protein D (SP-D) is a 43-kDa member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. The SP-D gene was targeted by homologous recombination in embryonic stem cells that were used to produce SP-D (− / −) mice. The SP-D (− / −) deficiency caused inflammation, increased oxidant production by isolated alveolar macrophages, abnormal surfactant structure and levels, and decreased SP-A expression. Therefore, disclosed is the SP-D (− / −) mouse as an excellent model for emphysema. Also included are models for testing emphysema therapies in the mouse model, methods for using SP-D protein or DNA as a treatment for emphysema and pulmonary infections, and diagnosis.

The pharmaceutical composition comprising the compound of the invention having 8-azaprostaglandin skeleton represented by formula (I) (wherein, all the symbols have the same meanings as that of the specification.) a salt thereof, a solvate thereof or a cyclodextrin clathrate thereof, or a prodrug thereof and them as active ingredient have EP4 agonistic action and thus are considered useful for the prevention and / or treatment of immunological diseases, asthma, neuronal cell death, arthritis, lung failure, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardial ischemia, systemic inflammatory response syndrome, sepsis, hemophagous syndrome, macrophage activation syndrome, Still's disease, Kawasaki disease, burn, systemic granulomatosis, ulcerative colitis, Crohn's disease, hypercytokinemia at dialysis, multiple organ failure, shock and glaucoma, etc. Furthermore, the compounds also have an action of accelerating bone formation, so it is expected to be useful for the prevention and / or treatment of diseases associated with loss in bone mass, for example, primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss, osteonecrosis, bone formation after bone operation, alternative treatment for bone grafting.

The invention relates to a pharmaceutical composition for treating lung diseases, and belongs to the field of traditional Chinese medicines. The drug is an orally administered preparation prepared from medical materials and pharmaceutically common auxiliary materials by a pharmaceutically common process, wherein the medical materials include honeysuckle, nepeta, peucedanum, fried radix cynanchi, almond, fritillaria, red tangerine peel, forsythia, fried stemona, aster, platycodon root, American ginseng, fried lily, reed root, fried ephedra, costazia bone, fructus perillae, fried loquat leaf, fried poppy shell, ledebouriella seseloides, skullcap, gypsum and licorice. Clinical tests prove that the pharmaceutical composition has good treatment effects on emphysema, pulmonary heart disease, asthma, phlegmatic chronic trachitis and other lung diseases.

The current invention provide novel compounds, methods of treating or preventing emphysema, cancer and dermatological disorders, pharmaceutical compositions suitable for the treatment or prevention of emphysema, cancer and dermatological disorders and methods for delivering formulations into the lung of a mammal suffering from emphysema, cancer and dermatological disorders.

The present invention relates to compounds according to formula (I), a process for preparing them, the intermediate compounds of the process and the use of the compounds in the manufacture of a medicament for use in treating diseases such as ARDS, pulmonary emphysema, bronchitis, bronchiectasis, COPD, asthma and rhinitis. The compounds are beta2 adrenoreceptor agonists.